KRSA · Korsana Biosciences, Inc. · Executive Compensation
$30.98
-0.93 (-2.90%)
At close · Sep 14
Going-concern doubt
— flagged Aug 4, 2026
Substantial doubt about the company's ability to continue as a going concern.
“Accordingly, we have concluded that substantial doubt exists about our ability to continue as a going concern.”View the 10-Q filed Aug 4, 2026
Market Cap
$21.34M
Shares
668,764
Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.
Fiscal 2022
| Executive | Role | Total |
|---|---|---|
| Cheryl Gault | Chief Operating Officer | $644,606 |
| Anjeza Gjino | Chief Financial Officer and Corporate Secretary | $625,421 |
| Peter M. Hecht | Ph.D., Chief Executive Officer | $590,257 |
Fiscal 2021
| Executive | Role | Total |
|---|---|---|
| Andreas Busch | Ph.D.,^\ ^ Chief Scientific Officer | $782,544 |
| Cheryl Gault | Chief Operating Officer | $664,345 |
| Peter M. Hecht | Ph.D., Chief Executive Officer | $108,220 |
Fiscal 2020
| Executive | Role | Total |
|---|---|---|
| Andreas Busch | Ph.D.,^\ ^ Chief Scientific Officer | $806,919 |
| Christopher Wright | M.D., Ph.D, Chief Medical Officer | $767,080 |
| Peter M. Hecht | Ph.D., Chief Executive Officer | $365,993 |
Fiscal 2019
| Executive | Role | Total |
|---|---|---|
| Andreas Busch | Ph.D.,\ Chief Scientific Officer | $3,251,107 |
Executive changes
| Person | Role | Change | Filed |
|---|---|---|---|
| Andrew Gottesdiener | member of the Audit Committee | Appointed | 2026-09-11 |
| Tomas Kiselak | Chair of the Board | Appointed | 2026-09-11 |
| Nimish Shah | Board | Appointed | 2026-09-11 |
| Jonathan Violin, Ph.D. | Board | Appointed | 2026-09-11 |
| Michelle Pernice | Board | Appointed | 2026-09-11 |
| Heidi Henson | Board | Appointed | 2026-09-11 |
| Tomas Kiselak | Board | Appointed | 2026-09-11 |
| Andrew Gottesdiener, M.D. | Board | Appointed | 2026-09-11 |
| Mark Vignola, Ph.D. | Chief Financial Officer | Appointed | 2026-09-11 |
| Matthew Leoni, M.D. | Chief Medical Officer | Appointed | 2026-09-11 |
| Jonathan Violin, Ph.D. | Chief Executive Officer and President | Appointed | 2026-09-11 |
| Rhonda M. Chicko | Chief Financial Officer | Resigned | 2026-09-11 |
| Regina M. Graul, Ph.D. | President and Chief Executive Officer | Resigned | 2026-09-11 |
| Steven E. Hyman, M.D. | board of directors | Resigned | 2026-09-11 |
| Dina Katabi, Ph.D. | board of directors | Resigned | 2026-09-11 |
| Michael Higgins | board of directors | Resigned | 2026-09-11 |
| Peter M. Hecht, Ph.D. | board of directors | Resigned | 2026-09-11 |
| Regina M. Graul, Ph.D. | board of directors | Resigned | 2026-09-11 |
| Errol B. De Souza, Ph.D. | board of directors | Resigned | 2026-09-11 |